These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17397100)

  • 21. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venlafaxine efficacy and tolerability in the treatment of post-stroke depression.
    Kucukalić A; Bravo-Mehmedbasić A; Kulenović AD; Suljić-Mehmedika E
    Psychiatr Danub; 2007 Jun; 19(1-2):56-60. PubMed ID: 17603417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the lower nitric oxide level cause cardiovascular changes in major depressed women?
    Arslan A; Uzun M
    Eur Rev Med Pharmacol Sci; 2008; 12(5):309-13. PubMed ID: 19024215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
    Kang EH; Lee IS; Chung SK; Lee SY; Kim EJ; Hong JP; Oh KS; Woo JM; Kim S; Park JE; Yu BH
    Psychiatry Res; 2009 Sep; 169(2):118-23. PubMed ID: 19695711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.
    Pae CU; Lim HK; Ajwani N; Lee C; Patkar AA
    Expert Rev Neurother; 2007 Jun; 7(6):603-15. PubMed ID: 17563244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venlafaxine: loss of antidepressant effect and its management.
    Sharma V
    J Clin Psychiatry; 1998 Jul; 59(7):381-2. PubMed ID: 9714268
    [No Abstract]   [Full Text] [Related]  

  • 27. Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine.
    Terhardt J; Lederbogen F; Feuerhack A; Hamann-Weber B; Gilles M; Schilling C; Lecei O; Deuschle M
    Clin Neuropharmacol; 2013; 36(6):198-202. PubMed ID: 24201230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults.
    Behlke LM; Lenze EJ; Pham V; Miller JP; Smith TW; Saade Y; Karp JF; Reynolds CF; Blumberger DM; Stefan C; Mulsant BH
    J Clin Psychopharmacol; 2020; 40(6):553-559. PubMed ID: 33044352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
    Kornstein SG
    Expert Rev Neurother; 2008 May; 8(5):737-42. PubMed ID: 18457530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study.
    Mumford JL; Wu K; Xia Y; Kwok R; Yang Z; Foster J; Sanders WE
    Environ Health Perspect; 2007 May; 115(5):690-4. PubMed ID: 17520054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and prognostic significance of QT prolongation in chronic renal failure patients.
    Voiculescu M; Ionescu C; Ismail G
    Rom J Intern Med; 2006; 44(4):407-17. PubMed ID: 18386617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression.
    Gonzalez-Pinto A; Gutierrez M; Gonzalez N; Elizagarate E; Perez de Heredia JL; Mico JA
    J Neuropsychiatry Clin Neurosci; 2002; 14(2):206-9. PubMed ID: 11983797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial.
    van Kerkhoven LA; Laheij RJ; Aparicio N; De Boer WA; Van den Hazel S; Tan AC; Witteman BJ; Jansen JB
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):746-52; quiz 718. PubMed ID: 18424191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting.
    Bukh JD; Jørgensen MB; Dam H; Plenge P
    Nord J Psychiatry; 2009; 63(4):347-51. PubMed ID: 19347769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autonomic tone attenuates drug-induced QT prolongation.
    Smith AH; Norris KJ; Roden DM; Kannankeril PJ
    J Cardiovasc Electrophysiol; 2007 Sep; 18(9):960-4. PubMed ID: 17666066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.